Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Allergan PLC, long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).
The analysis of the financial turnover ratios over the examined quarters reveals distinct trends in asset utilization and equity efficiency. These metrics provide insight into the company's operational effectiveness over time.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio displays a gradual decline from 9.93 in the first quarter of 2016 to 8.4 by the first quarter of 2020. This trend indicates a slight decrease in revenue generated per unit of net fixed assets. Despite some fluctuations, the ratio remains relatively stable around the mid-8 to low-9 range, suggesting consistent but slightly diminishing efficiency in using fixed assets to generate sales.
- Net Fixed Asset Turnover (Including Operating Lease, Right-of-Use Asset)
- When including operating leases and right-of-use assets, the turnover ratio starts identically to the standard net fixed asset turnover but follows a more pronounced downward trend after late 2018. It drops from 8.83 at the end of 2018 to approximately 6.72 by the first quarter of 2020. This decline may reflect the impact of incorporating lease-related assets, resulting in a larger asset base and therefore lower turnover, signaling a change in asset structure or lease accounting policies affecting asset efficiency metrics.
- Total Asset Turnover
- The total asset turnover consistently increases from 0.12 in early 2016 to 0.18 by the first quarter of 2020. This upward trend indicates improved efficiency in utilizing the entire asset base to generate sales. The steady growth suggests successful management of total assets, enhancing revenue generation relative to asset size.
- Equity Turnover
- Equity turnover exhibits a progressive increase from 0.21 at the start of 2016 up to 0.28 in early 2020. This gradual rise reflects enhanced utilization of shareholder equity to drive sales, indicating growing operational effectiveness and possibly improved profitability over the period.
Overall, the data show a mild reduction in the efficiency of fixed asset use, particularly when accounting for lease assets, while total asset and equity turnover trends demonstrate ongoing improvements in leveraging resources to generate revenue. This mixed pattern may point to evolving asset composition and operational strategies impacting the company’s asset and equity utilization.
Net Fixed Asset Turnover
Allergan PLC, net fixed asset turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | ||||||
| Property, plant and equipment, net | 1,915,400) | 1,926,500) | 1,857,000) | 1,821,000) | 1,781,100) | 1,787,000) | 1,756,600) | 1,761,400) | 1,769,500) | 1,785,400) | 1,802,200) | 1,750,100) | 1,659,300) | 1,611,300) | 1,566,300) | 1,557,200) | 1,602,400) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | 8.40 | 8.35 | 8.52 | 8.61 | 8.82 | 8.83 | 9.13 | 9.17 | 9.06 | 8.93 | 8.59 | 8.61 | 8.89 | 9.04 | 8.54 | 8.89 | 9.93 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).
1 Q1 2020 Calculation
Net fixed asset turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Property, plant and equipment, net
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 1,915,400 = 8.40
2 Click competitor name to see calculations.
- Net Revenues
- The net revenues exhibit a cyclical pattern with significant quarterly fluctuations over the observed period. Beginning at approximately $3.4 billion in the first quarter of 2016, the revenue generally increases toward the end of each year, peaking in the fourth quarter of 2017 at over $4.3 billion. This seasonal trend continues, with revenues in the fourth quarter consistently surpassing those in the first quarter of each year.
- Notably, the first quarter revenues tend to be the lowest within each year, with slight declines observed at the start of 2017, 2018, 2019, and 2020 relative to their prior year's corresponding quarter. The highest quarterly revenue was recorded near the end of 2019, slightly exceeding $4.35 billion, after which a noticeable drop occurred in the first quarter of 2020 to about $3.6 billion.
- Property, Plant and Equipment, Net
- The net value of property, plant, and equipment shows a general upward trend throughout the period. Starting from approximately $1.6 billion in early 2016, there is a steady increase peaking at around $1.93 billion by the third quarter of 2019 and remaining close to that level into the first quarter of 2020.
- Despite minor decreases in specific quarters, the overall asset base appears to be expanding, indicating continued investment or acquisition of fixed assets. This growth in net fixed assets suggests efforts to maintain or increase productive capacity.
- Net Fixed Asset Turnover
- The ratio of net fixed asset turnover, which measures efficiency in using fixed assets to generate revenues, shows a declining trend over the observed period. Starting at a high of 9.93 in the first quarter of 2016, the ratio decreases to approximately 8.40 by the first quarter of 2020.
- This downward trend indicates a reduction in the efficiency of asset utilization; although the company is investing in fixed assets, as indicated by the increase in property, plant, and equipment, the revenue generated per unit of fixed asset value is gradually declining. This may be partially attributed to the fluctuating and sometimes declining quarterly revenues.
- Overall Analysis
- The company’s financial trends reveal increasing fixed asset investment alongside variable revenue performance with seasonal characteristics. While growing property, plant, and equipment values demonstrate capital expansion, the decreasing net fixed asset turnover ratio suggests a diminishing return on these asset investments over time.
- Seasonal revenue patterns consistently show higher volumes in the latter quarters of each year, with lower performances at the year's start. The notable dip in revenues at the beginning of 2020 may warrant further investigation to assess underlying causes and potential impact on operational efficiency.
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Allergan PLC, net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | ||||||
| Property, plant and equipment, net | 1,915,400) | 1,926,500) | 1,857,000) | 1,821,000) | 1,781,100) | 1,787,000) | 1,756,600) | 1,761,400) | 1,769,500) | 1,785,400) | 1,802,200) | 1,750,100) | 1,659,300) | 1,611,300) | 1,566,300) | 1,557,200) | 1,602,400) | ||||||
| Right of use asset, operating leases | 481,000) | 490,400) | 478,200) | 457,900) | 455,400) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Property, plant and equipment, net (including operating lease, right-of-use asset) | 2,396,400) | 2,416,900) | 2,335,200) | 2,278,900) | 2,236,500) | 1,787,000) | 1,756,600) | 1,761,400) | 1,769,500) | 1,785,400) | 1,802,200) | 1,750,100) | 1,659,300) | 1,611,300) | 1,566,300) | 1,557,200) | 1,602,400) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 6.72 | 6.66 | 6.77 | 6.88 | 7.03 | 8.83 | 9.13 | 9.17 | 9.06 | 8.93 | 8.59 | 8.61 | 8.89 | 9.04 | 8.54 | 8.89 | 9.93 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).
1 Q1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 2,396,400 = 6.72
2 Click competitor name to see calculations.
- Net Revenues
- Net revenues exhibit noticeable fluctuations over the observed periods without a clear long-term upward or downward trend. Initial quarters in 2016 show moderate growth, peaking towards the end of 2017 and 2019, with revenues reverting to lower levels at the start of subsequent years. This cyclical pattern suggests seasonal or cyclical influences on the company's revenue generation.
- Property, Plant and Equipment, Net
- The net value of property, plant, and equipment (including operating lease right-of-use assets) shows a steady and consistent increase across the periods. Beginning around 1.6 billion USD in early 2016, the asset base expands to nearly 2.4 billion USD by the first quarter of 2020. This growth suggests ongoing investment or asset capitalization, potentially reflecting expansion or modernization efforts.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio, measuring revenue generated per unit of fixed assets, reveals a declining trend over time. Starting from a high near 9.9 in early 2016, the ratio gradually decreases, dropping below 7.0 by early 2020. Despite some minor fluctuations, the overall direction indicates that revenue growth is not keeping pace with the increase in fixed assets, which may suggest diminishing efficiency or utilization of property and equipment.
Total Asset Turnover
Allergan PLC, total asset turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | ||||||
| Total assets | 88,426,200) | 94,699,100) | 94,408,900) | 95,480,700) | 98,036,300) | 101,787,600) | 106,542,500) | 108,858,800) | 112,021,300) | 118,341,900) | 118,992,800) | 124,734,800) | 126,836,900) | 128,986,300) | 143,607,700) | 132,619,100) | 136,073,700) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.09 | 0.10 | 0.12 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).
1 Q1 2020 Calculation
Total asset turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Total assets
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 88,426,200 = 0.18
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals distinct trends in net revenues, total assets, and total asset turnover for the observed periods.
- Net Revenues
- Net revenues exhibit a fluctuating pattern with notable seasonal variances. Initial quarters in 2016 show gradual growth, peaking in the fourth quarter. However, a dip is observed at the start of 2017, followed by a recovery and a new peak at the end of 2017. The revenue then decreases in early 2018 but rebounds mid-year, maintaining relatively high magnitudes through 2018 and 2019, with end-of-year quarters generally showing increased values. The first quarter of 2020 records a decline in revenues compared to the previous quarter, suggesting possible cyclical or external impact factors influencing sales performance.
- Total Assets
- Total assets demonstrate a consistent downward trend throughout the observed period. Starting from a peak of over 136 billion US dollars in early 2016, the asset base declines steadily quarter over quarter, reaching approximately 88 billion by the first quarter of 2020. This reduction indicates possible asset disposals, amortization, impairment, or strategic restructuring leading to lower asset holdings.
- Total Asset Turnover Ratio
- The total asset turnover ratio shows a positive and steady increase across the same timeframe. Beginning at 0.12 in early 2016, this ratio gradually rises to 0.18 by the first quarter of 2020. This indicates improved efficiency in generating revenues from asset investments despite the overall decrease in asset size, suggesting enhanced operational effectiveness or a shift towards less capital-intensive business activities.
In summary, while net revenues display seasonal variability without a clear long-term growth trajectory, total assets have consistently decreased, reflecting potential strategic realignments or downsizing. Concurrently, the improving asset turnover ratio suggests an increase in asset utilization efficiency, which may compensate for shrinking asset volume by generating more revenue per asset unit.
Equity Turnover
Allergan PLC, equity turnover calculation (quarterly data)
| Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net revenues | 3,604,400) | 4,351,000) | 4,050,700) | 4,090,100) | 3,597,100) | 4,079,700) | 3,911,400) | 4,124,200) | 3,672,100) | 4,326,100) | 4,034,300) | 4,007,400) | 3,572,900) | 3,864,300) | 3,622,200) | 3,684,800) | 3,399,300) | ||||||
| Shareholders’ equity | 57,997,700) | 58,173,600) | 58,475,200) | 59,674,700) | 61,542,000) | 65,114,100) | 70,507,800) | 71,243,500) | 72,327,900) | 73,821,100) | 71,159,400) | 75,220,400) | 75,188,400) | 76,192,700) | 89,725,900) | 76,643,900) | 77,450,000) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.24 | 0.23 | 0.23 | 0.22 | 0.22 | 0.22 | 0.20 | 0.20 | 0.19 | 0.15 | 0.18 | 0.21 | ||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Bristol-Myers Squibb Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Eli Lilly & Co. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Merck & Co. Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Pfizer Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).
1 Q1 2020 Calculation
Equity turnover
= (Net revenuesQ1 2020
+ Net revenuesQ4 2019
+ Net revenuesQ3 2019
+ Net revenuesQ2 2019)
÷ Shareholders’ equity
= (3,604,400 + 4,351,000 + 4,050,700 + 4,090,100)
÷ 57,997,700 = 0.28
2 Click competitor name to see calculations.
- Net Revenues
- The net revenues exhibit a fluctuating pattern over the observed quarters. Initially, revenues increased from approximately 3.4 billion to 3.9 billion dollars during 2016. However, in 2017, revenues showed a similar trend of growth throughout the year, peaking at over 4.3 billion dollars in the last quarter. In 2018, revenues again fluctuated, reaching near 4.1 billion dollars in the final quarter. During 2019, the revenue levels remained relatively steady with a slight increase towards the year's end, peaking again at approximately 4.35 billion dollars. By the first quarter of 2020, revenues declined to around 3.6 billion dollars, indicating a downward movement at the start of the year.
- Shareholders’ Equity
- Shareholders' equity followed a generally declining trend across the period. It started around 77.5 billion dollars in early 2016 with some fluctuations, reflecting a peak near 89.7 billion dollars in the third quarter of 2016. Afterward, equity showed a marked decrease, diminishing steadily through subsequent years. By the end of 2018, equity had decreased to about 65.1 billion dollars and continued its downward trend into 2019 and early 2020, ultimately reaching approximately 58 billion dollars.
- Equity Turnover Ratio
- The equity turnover ratio demonstrated a consistent upward trajectory over the examined periods. Beginning at 0.21 in the first quarter of 2016, the ratio slightly declined in mid-2016 and later began a steady increase from late 2016 onwards. By early 2017, the ratio stabilized around 0.20 to 0.22, and then progressively climbed throughout 2018 and 2019, reaching 0.28 by the first quarter of 2020. This indicates increasing efficiency in generating revenues relative to shareholders' equity over time.